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18 ABSTRACT: Porous silicon nanoparticles (PSiNPs) and gold
19 nanorods (AuNRs) can be used as biocompatible nanocarriers
20 for delivery of therapeutics but undesired leakage makes them
21 inefficient. By encapsulating the PSiNPs and AuNRs in a
22 hydrogel shell, we create a biocompatible functional nano-
23 carrier that enables sustained release of therapeutics. Here, we
24 report the fabrication of AuNRs-conjugated PSi nanoparticles
25 (AuNRsPSiNPs) through two-step chemical reaction for high-
26 capacity loading of hydrophobic and hydrophilic therapeutics
27 with photothermal property. Furthermore, using water-in-oil
28 microemulsion templates, we encapsulate the AuNRsPSiNPs
29 within a calcium alginate hydrogel nanoshell, creating a versatile biocompatible nanocarrier to codeliver therapeutics for
30 biomedical applications. We find that the functionalized nanohydrogel effectively controls the release rate of the therapeutics
31 while maintaining a high loading efficiency and tunable loading ratios. Notably, combinations of therapeutics coloaded in the
32 functionalized nanohydrogels significantly enhance inhibition of multidrug resistance through synergism and promote faster
33 cancer cell death when combined with photothermal therapy. Moreover, the AuNRs can mediate the conversion of near-infrared
34 laser radiation into heat, increasing the release of therapeutics as well as thermally inducing cell damage to promote faster cancer
35 cell death. Our AuNRsPSiNPs functionalized calcium alginate nanohydrogel holds great promise for photothermal combination
36 therapy and other advanced biomedical applications.
37 KEYWORDS: Calcium alginate nano hydrogel, gold nanorods conjugated porous silicon nanoparticles, photothermal therapy,
38 multidrug resistance inhibition, biomedical applications
39 Conventional cancer therapy does not distinguish between40 cancerous and healthy cells in a significant way.1,2
41 Fortunately, recent developments such as photothermal therapy
42 has the ability to target the tumor cells and minimize the
43 damage to adjacent normal tissues.3 Controlled release of
44 therapeutics is another effective way to enhance in vivo
45 therapeutic efficacy, especially when used with synergistic
46 combinations of drugs,1,2 which inhibit multidrug resistance3
47 and reduce side effects.4 However, creating a single
48 biocompatible nanocarrier that allows high-efficiency coloading
49of multiple therapeutics, controllable release, and targeted
50therapy presents a great challenge for encapsulation and release
51technology.
52Porous silicon nanoparticles (PSi NPs)
5−8 are biocompatible
53and biodegradable nanocarriers for codelivery of therapeutics as
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54 they have a high loading capacity due to their high surface-area-
55 to-volume ratio. By chemically modifying the PSi NPs surface
56 group and conjugating them with targeting agents to increase
57 cellular uptake,6,9 PSi NPs have been shown to enhance
58 delivery efficiency and reduce side effects due to improved
59 localization in tumors. Gold nanorod (AuNR) is an FDA
60 approved drug carrier and therapeutic agent; several AuNR
61 based formulations are in phase I clinical trial. They are also
62 often utilized in photothermal therapy10,11 and in triggered
63 drug release and photoacoustic imaging10−12 due to their
64 unique optical properties. However, therapeutics release from
65 both PSi NPs and AuNRs is fast and not controllable within the
66 body.13,14
67 Encapsulation of AuNRs conjugated PSi NPs within a
68 biocompatible hydrogel shell overcomes the quick leakage
69 limitation while enabling their advantages to be used in cancer
70 therapy.15 We synthesize novel gold nanorods conjugated
71porous silicon nanoparticles (AuNRsPSiNPs) cores with
72photothermal properties to coload hydrophobic and hydro-
73philic therapeutics and encapsulate them within a biocompat-
74ible calcium alginate hydrogel using water-in-oil microemulsion
75 s1templates through cross-linking the shell (Scheme 1). We
76quantify the release profile of the AuNRsPSiNPs-in-calcium
77alginate nanocarriers for both hydrophilic and hydrophobic
78therapeutics. Finally, we demonstrate the nanocarriers’
79biomedical application in photothermal combination therapy.
80We synthesize hydrophilic short gold nanorods about 50 nm
81 f1in size, shown in the TEM micrograph in Figure 1a. Functional
82PSi NPs with carboxyl (COOH) surface groups are fabricated
83using electrochemical anodization,7 yielding an average particle
84size of 129.2 ± 34.3 nm and zeta-potential of 63.01 ± 0.6 mV.
85AuNRsPSiNPs are synthesized through a two-step reaction at
8625 °C. The carboxyl groups of PSi NPs are reacted with the
87amine group of cysteamine (H2NCHCH2SH) through N-(3-
Scheme 1. Formation of Biocompatible Gold Nanorods Conjugated Porous Silicon Nanoparticles Functionalized Calcium
Alginate Nanohydrogel Using Water-in-Oil Microemulsion Templates through Crosslinking as a Versatile Therapeutics Co-
Delivery Nanocarrier for Photothermal Therapy
Figure 1. Morphology study of gold nanorods, AuNRsPSiNPs, calcium alginate nanohydrogel and AuNRsPSiNPs functionalized calcium alginate
nanohydrogel. (a) TEM image of gold nanorods. The scale bar denotes 50 nm. (b) SEM image of AuNRsPSiNPs. The scale bar denotes 100 nm. (c)
XPS spectrum of the gold nanorods conjugated porous silicon nanoparticles. (d) SEM image of calcium alginate nanohydrogel. The scale bar




Nano Lett. XXXX, XXX, XXX−XXX
B
88 (dimethylamino)propyl)-N′-ethylcarbodiimide hydrochloride
89 (EDC) mediated reaction, after which the PSi-CON−
90 CHCH2−HS with HS surface groups is easily connected with
91 the gold nanorods. The morphology of the AuNRsPSiNPs
92 nanoparticles is shown by scanning electron microscopy (SEM)
93 in Figure 1b. We use X-ray photoelectron spectroscopy (XPS)
94 to confirm the successful formation of AuNRsPSiNPs, as shown
95 by the C, N, O, S, Si, and Au peaks (Figure 1c).
96 We use biocompatible water-in-oil microemulsions as water
97 core microreactors to produce calcium alginate hydrogel shells
98 to encapsulate AuNRsPSiNPs that has been preloaded with
99 therapeutics. AuNRsPSiNPs are first loaded with hydrophobic
100 molecular targeting therapeutics, Afatinib, Docetaxel, or
101 Erlotinib. Then, a mixture of hydrophilic antibody, therapeutic
102 DOX,16 and the AuNRsPSiNPs are dissolved in a 1−2 wt %
103 sodium alginate solution, followed by mixing with a 0.3 M
104 AOT-isooctane oil phase to form a w/o microemulsion. Finally,
105 the w/o microemulsion is cross-linked by pump-controlled
106 dropwise addition of another w/o microemulsion containing
107 dilute CaCl2 solution, as shown in Scheme 1. Images of calcium
108 alginate nanohydrogels with and without AuNRs-S-PSi loaded
109 with therapeutics, taken by SEM, are shown in Figure 1d,e,
110 respectively. The nanohydrogel size can be controlled by tuning
111 the molar ratio between the water and oil phases.17 The
112 diameter of nanohydrogels without nanoparticles is about 120
113 nm, while the diameter of nanohydrogels encapsulating
114 nanoparticles is about 250 nm. Si, Au, S, and Ca peaks in the
115 SEM-energy dispersive X-ray spectrum (Figure S1a) confirm
116 the successful encapsulation of AuNRsPSiNPs within the
117 calcium alginate nanohydrogel. The hydrodynamic diameter
118 of the AuNRsPSiNPs functionalized calcium alginate nano-
119 hydrogel is measured by dynamic light scattering (DLS) at 298
120 K (Figure S1b).
121 To confirm the biocompatibility of the AuNRs-S-PSi
122 nanoparticles and the AuNRsPSiNPs functionalized calcium
123 alginate nanohydrogels, we expose MCF-7, SKBR-3, and MDA-
124 MB-231 breast cancer cells to different concentrations of the
125 nanocarriers and assess viability after 24 h of incubation at 37
126 °C. The cell viability rate decreases from 95% to 75% with
127 increasing AuNRsPSiNPs concentrations from 50 μg/mL to
f2 128 400 μg/mL (Figure 2a), and decreases from 95% to 80% with
129increasing AuNRsPSiNPs functionalized calcium alginate nano-
130hydrogel concentrations from 100 μg/mL to 1000 μg/mL
131(Figure 2b). Notably, cell viability in the presence of 100 μg/
132mL nanohydrogel containing 10 nM AuNRs is 95.3 ± 3.8%.
133Calcium alginate nanohydrogel as the shell of the AuNRs-
134PSiNPs is much more biocompatible than the AuNRsPSiNPs
135alone. All cell viability and cytotoxicity results confirm that the
136prepared AuNRsPSiNPs and AuNRsPSiNPs functionalized
137nanohydrogel are cytocompatible. Thus, they are potentially a
138suitable therapeutics codelivery nanocarrier for many bio-
139medical applications.
140The UV absorption curves for standard concentrations of
141DOX solutions, AuNRs, and the DOX- or AuNRs-loaded
142nanohydrogel solutions are measured at 488 and 975 nm using
143a UV−vis spectrophotometer. The initial and the total released
144concentration of hydrophobic therapeutics Afatinib and
145Docetaxel are measured by high-performance liquid chroma-
146tography (HPLC). The drug encapsulation efficiency and
147loading degree is then calculated based on the initial drug
148concentration and total release concentration. We find that the
149loading degree of hydrophobic therapeutics in AuNRsPSiNPs
150core is above 10% but the total decreases slightly after the
151nanohydrogel encapsulation step, while the loading degree of
152hydrophilic therapeutics in the nanohydrogel is about 10%.
153In vitro dynamic dialysis release of therapeutics including
154DOX, antibody, Docetaxel, and Afatinib from free solution, PSi
155NPs, AuNRsPSiNPs, and AuNRsPSiNPs functionalized calcium
156alginate nanohydrogel into solutions imitating blood (PBS pH
1577.4) and acidic tumor (pH 5.2) environments are carried out
158using a minidialysis kit at 37 °C. The release profile of DOX
159from free solution, PSi NPs and AuNRsPSiNPs into pH 7.4 and
160pH 5.2 phosphate buffered saline (PBS) solutions is shown in
161 f3Figure 3a,b, and Figure S2. The in vitro release studies indicate
162that no initial burst release occurs and that 90−100% of the
163drug is released from the nanoparticles suspension into the
164release medium within 24 h. The release of DOX from the
165AuNRsPSiNPs suspension (80% of drug released at 12 h) is
166much slower than the dissolution profile of free DOX and the
167DOX release from PSi NP (80% of drug released at less than 2
168h), possibly due to the ability of gold nanorods to bind
169hydrophilic drugs, thus delaying release. The release profile of
170therapeutics including DOX, Afatinib, Docetaxel, and antibody
171from AuNRsPSiNPs functionalized calcium alginate nano-
172hydrogel into PBS pH 7.4 or pH 5.2 buffer solutions at 37 °C is
173shown in Figure 3c,d. The AuNRsPSiNPs encapsulated in
174calcium alginate nanohydrogel platform releases therapeutics
175much slowly than both PSi NPs and AuNRsPSiNPs, indicating
176successful protection of therapeutics by the calcium alginate
177shell (80% of drug released at 20 h at pH 7.4). Moreover, the
178therapeutics release rate increases in an acidic environment
179(80% of drug released at 12 h).
180The plasmonic resonance peak of AuNRs is at 975 nm, which
181well distinguish them from the surrounding tissue and enable
182them for better biomedical applications. In addition, gold
183nanorods carrying hydrophilic therapeutics can also trigger
184release of DNA oligonucleotides18 and anticancer drug
185doxorubicin with heat induced by laser irradiation. The in
186vitro release of DOX from the functionalized nanohydrogel into
187PBS buffer in the presence of gold nanorods under laser
188irradiation at 808 nm is much faster than the typical release rate
189of 24 h. Over 90% of DOX is released within 30 min (Figure
1903e,f), indicating the potential of photothermal therapy using
191NIR laser irradiation.
Figure 2. Biocompatibility study of AuNRsPSiNPs and AuNRsPSiNPs
functionalized calcium alginate nano hydrogel on MCF-7, SKBR-3,
and MDA-MB-231 cells at 310 K. (a) The cell viability of
AuNRsPSiNPs on MCF-7, SKBR-3, and MDA-MB-231 cells after
24 h incubation at 310 K (10 nM AuNRs set up as control; n = 3,
mean ± SD). (b) The cell viability of AuNRsPSiNPs functionalized
calcium alginate nano hydrogel on MCF-7, SKBR-3, and MDA-MB-
231 cells after 24 h incubation at 310 K (10 nM AuNRs within 200
μg/mL PSi set up as control; n = 3, mean ± SD).
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192 To demonstrate synergistic effects of the therapeutics
193 combinations, we conduct in vitro cell viability study with
194 several therapeutics alone and in combination on both HER2-
195 positive and -negative breast cancer cells, and EGFR-positive
196 nonsmall cell lung cancer (NSCLC) NCl-H2087 cells, shown
f4 197 in Figure 4a,b. The combinations do exhibit synergism:19
198 adding a HER2/EGFR dual molecular-targeting drug Afatinib
199 enhances treatment efficiency compared with using DOX alone
200 against HER2/EGFR-positive cells. The combination of
201 Afatinib and Docetaxel also behaves synergistically to induce
202 more cell death in different cancer cell types.
203Not only are the drug combinations more effective at
204inducing cell death, but they also have an added advantage of
Figure 3. In vitro therapeutics release study. (a,b) Level of DOX from
free solution, PSi NPs and AuNRsPSiNPs in PBS or pH 5.2 buffer
containing 0.1 wt % Tween80 were release under magnetic stirring at
various pH values. Each point represented the average of three
measurements with standard deviation. (c) The in vitro therapeutics of
DOX, Docetaxel, Afatinib, and antibody (488 nm fluorescent
antibody) release from AuNRsPSiNPs functionalized calcium alginate
nanohydrogel into PBS buffer containing 0.1 wt % Tween 80 at 310 K.
Each point represented the average of three measurements with
standard deviation. (d) The in vitro therapeutics of DOX, Docetaxel,
Afatinib, and antibody (488 nm fluorescent antibody) release from
AuNRsPSiNPs functionalized calcium alginate nanohydrogel into pH
= 5.2 buffer containing 0.1 wt % Tween80 at 310 K. Each point
represented the average of three measurements with standard
deviation. (e,f) The UV−vis spectrum and the photothermal release
of DOX (488 nm) and AuNRs (975 nm) from nanohydrogel under
808 nm laser irradiation at different time intervals and the
photothermal effects on the release of DOX from nanoplatform
under laser irradiation.
Figure 4. Synergism, multidrug resistance inhibition, HER2 (pY1248)
and human plasma stability study. (a) The isobologram of two drugs
combination of DOX+Afatinib on killing SKBR-3, MDA-MB-231 and
MCF-7 cells at 37 °C. In the simulation, Afatinib has an IC50
(concentration giving 50% inhibition) of 500 au (arbitrary units),
and IC50 of drug DOX is 100 au. (b) The isobologram of two drugs
combination of Docetaxel and Afatinib on killing HER2 positive breast
cancer SKBR-3 cells and EGFR positive nonsmall cell lung cancer
NCl-H2087 cells, and breast cancer MDA-MB-231 cells at 37 °C. In
the simulation, Docetaxel has an IC50 (concentration giving 50%
inhibition) of 500 au (arbitrary units), IC50 of drug Afatinib is 100
au(c) The multidrug resistance inhibition on Afatinib-resistant SKBR-
3/AR cells by Afatinib, Docetaxel, A+DCTX, Capecitabine and A +
Cap loaded nanoplatform after 24 h incubation (CA/CDCTX = 1:1 and
CA/CCap = 1:1) at 310 K. (d) Cell viability of Afatinib, Afatinib
+Docetaxel loaded nano hydrogel under laser irradiation at 808 nm at
different time intervals or without laser irradiation on SKBR-3/AR
cells after 2 h incubation using live/dead assay. (e) Human HER2
(pY1248) detection assay on HER2 positive breast cancer SKBR3 cells
by anti-HER2 antibody (Ab), Afatinib (A), DOX(D), A+D, Ab+A, A
+Ab, Ab+A+D after 16 h of treatment at 37 °C. (200 μ g/mL
AuNRsPSiNPs functionalized calcium alginate nanohydrogel set as
control; CAfatinib/CD = 1:1; the concentration of anti-HER2 anitbody is
20 μg/mL; the total drugs concentration is 10 μ g/mL) (f) The
human plasma stability of Docetaxel, Afatinib and Erlotinib from the
AuNRs PSiNPs functionalized calcium alginate nanohydrogel. The
percentage of parent compound remaining after incubation in human
plasma is plotted versus incubation time. All incubations are performed
in triplicated using 96 well cell culture plate. Each point represents the
average of three measurements with standard deviation.
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205 inhibiting multidrug resistance. We incubate Doxorubicin-
206 resistant MCF-7/DOX cells (a model multidrug resistant
207 breast cancer cell) and Afatinib-resistant SKBR-3/AR cells
208 (HER2 positive multidrug resistant breast cancer cell) for 24 h
209 at 37 °C in the presence of single drug solutions or nanocarriers
210 loaded with therapeutics combinations. As shown in Figure 4c
211 and Figure S3a−c, the cells are highly resistant to both DOX
212 and Afatinib alone, but the therapeutic combinations cause
213 enhanced cytotoxicity due to synergistic effects; moreover, at
214 the same concentration, the therapeutic combinations are much
215 more cytotoxic to drug-resistant cells than the individual
216 therapeutics. In particular, Docetaxel significantly enhances
217 killing of MCF-7/DOX or SKBR-3/AR cells when combined
218 with DOX or Afatinib.
219 By incorporating photothermal treatment, the therapeutics
220 can be delivered locally with high efficiency. We further
221 perform in vitro cell viability testing on the MCF-7/DOX and
222 SKBR-3/AR cells with and without 808 nm laser irradiation at
223 different time intervals, followed by incubation for 2 h at 37 °C.
224 The cytotoxicity rate remains relatively low without laser
225 irradiation due to the slow natural release of therapeutics, as
226 shown in Figure 4d and Figure S3d. However, laser irradiation
227 dramatically increases cell death, especially with the therapeutic
228 combination, after 30 min of laser irradiation. The AuNRs
229 mediate the conversion of near-infrared radiation into heat,
230 causing the fast release of therapeutics (see Figure S2) as well
231 as a local temperature increase that thermally induces cell
232 damage, while the released therapeutic combination functions
233 to significantly inhibit multidrug resistance and promote cancer
234 cell death. Using photothermal effects enables a quick, localized
235 treatment procedure that avoids multidrug resistance for
236 improved combination therapy. ATP assay using the same
237 method according to our previous work15 shows that
238 therapeutics combination has synergism on HeLa cells,
239 shown in Figure S4.
240 Treatment specificity can be further enhanced by including
241 an anti-HER2 antibody. The quantify HER2(pY1248) protein
242 in HER2-positive SKBR-3 breast cancer cells was detected
243 using an ELISA assay, for which the cells treated with
244 therapeutics for 16 h with and without anti-HER2 antibody
245 in the nanohydrogel were lysed and analyzed. HER2-targeted
246 therapeutics and the anti-HER2 antibody can effectively reduce
247 HER2 (pY1248) expression alone, but the combination of
248 Afatinib, Docetaxel and anti-HER2 antibody is the most
249 effective formulation of the tested combinations to induce
250 HER2-positive breast cancer cell death, as seen in Figure 4e.
251 Additionally, we quantify full-length HER2 and EGFR
252 protein levels in lysates of HER2 positive SKBR-3 breast
253 cancer cells and EGFR positive HeLa cells after 6 h of
254 treatment with single drugs and drug combinations with and
255 without anti-HER2/EFGR antibody. Figure S5 represents a
256 clear decrease in HER2/EGFR protein levels after treatment by
257 molecular targeting therapeutics and anti-HER2/EGFR anti-
258 body. Moreover, the HER2/EGFR targeting therapeutic and
259 anti-HER2/EGFR antibody combination has high targeted
260 killing selectivity which results in lowest HER2/EGFR protein
261 level that irreversibly inhibits HER2/EGFR-positive cancer
262 cells. Using Afatinib and Erlotinib, both EGFR targeting drugs,
263 in combination further promotes EGFR-positive cancer cell
264 death, while Docetaxel inhibits the cancer cell growth and
265 migration.
266 Lastly, we perform a human plasma stability assay to
267 determine the stability of the tested compounds (therapeutics
268Afatinib, Erlotinib, and Docetaxel) in plasma.15 Within the
269AuNRsPSiNPs functionalized calcium alginate nanohydrogel,
270about 90% of the therapeutics remained after a 120 min
271incubation (Figure 4f). The therapeutics that are protected by
272AuNRsPSiNPs and the calcium alginate hydrogel shell are very
273stable in human plasma, suggesting potential for high
274performance in vivo and for clinical applications.
275In conclusion, we demonstrate a novel biocompatible
276nanocarrier that codelivers therapeutics combinations with
277controllable release and photothermal properties for improved
278combination therapy. We synthesize gold nanorods conjugated
279porous silicon nanoparticles (AuNRsPSiNPs) and show that
280the AuNRsPSiNPs have a high loading capacity for therapeutics
281and their release can be controlled by the nanoparticles’
282photothermal properties. We successfully encapsulate the NPs
283within a calcium alginate nanohydrogel shell using water-in-oil
284microemulsion templates. These functionalized calcium alginate
285nanohydrogels exhibit excellent encapsulation efficiency,
286controllable release, low toxicity to normal cells, high loading
287capacity of therapeutics and photothermal properties. More-
288over, we show that the therapeutics combinations significantly
289enhance cancer cell death and inhibit multidrug resistance
290through drug synergy and molecular targeting selectivity.
291Importantly, laser irradiation activates the nanoparticle photo-
292thermal properties to enable fast release of therapeutics and a
293local temperature increase for near-infrared laser photothermal
294therapy. Furthermore, incorporating anti-EGFR/HER2 anti-
295body and EGFR/HER2 dual-targeted therapeutics more
296effectively reduces EGFR/HER2 protein expression when
297combined synergistically with one another or with other
298therapeutics. This work shows that a biocompatible nanocarrier
299comprised of gold nanorods conjugated porous silicon
300nanoparticles functionalized calcium alginate nanohydrogels
301holds great promise in the codelivery of various therapeutics
302with many properties suitable for biomedical applications,
303including multidrug-resistant cancer treatments and photo-
304thermal-assisted targeted combination therapy.
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328 Heĺder A. Santos: 0000-0001-7850-6309
329 David A. Weitz: 0000-0001-6678-5208
330 Present Addresses
331
○(H.K.) Cambridge International Curriculim Centre of Beijing
332 Normal University, Beijing 100009, China, PR China.
333
◆(D.C.) College of Chemical and Biological Engineering,




337 H.Z., Y.Z., L.Q., H.W., and H.K. have equal contribution to
338 this work
339 Notes
340 The authors declare no competing financial interest.
341 ■ ACKNOWLEDGMENTS
342 The authors are grateful to the Fundamental Research Funds
343 for the Central Universities (No. FRF-BR-09-021B), 863 (No.
344 2006AA03Z108) program of China; NSF (DMR-1310266) and
345 Harvard MRSEC (DMR-0820484) for financial support. H.Z.
346 acknowledges Jane and Aatos Erkko Foundation (Grant
347 4704010), Academic of Finland (Grant 297580) and Sigrid
348 Juselius Foundation (Grant 28001830K1) for financial support.
349 H.A.S. acknowledges financial support from the Sigrid Juselius
350 Foundation (Decision No. 4704580), and the European
351 Research Council under the European Union’s Seventh
352 Framework Programme (FP/2007-2013, Grant No. 310892).
353 Cell experiments, AFM, XPS, SEM, SEM-EDX, DLS, HPLC,
354 TEM, laser irradiation, ATP and Human HER2/EGFR ELISA
355 were conducted at the Harvard CNS and FAS center. We thank
356 Timothy J. Cavanaugh at Harvard CNS for SEM-EDX
357 measurement and Dr. Arthur McClelland at Harvard CNS for
358 help with NIR laser irradiation experiments.
359 ■ REFERENCES
(1)360 Jabir, N. R.; Tabrez, S.; Ashraf, G. M.; Shakil, S.; Damanhouri, G.
361 A.; Kamal, M. A. Int. J. Nanomed. 2012, 7, 4391−4408.
(2)362 Kolishetti, N.; Dhar, S.; Valencia, P. M.; Lin, L. Q.; Karnik, R.;
363 Lippard, S. J.; Langer, R.; Farokhzad, O. C. Proc. Natl. Acad. Sci. U. S.
364 A. 2010, 107 (42), 17939−17944.
(3)365 Torchilin, V. P. Adv. Drug Delivery Rev. 2006, 58 (14), 1532−
366 1555.
(4)367 Kong, F.; Zhang, X.; Zhang, H.; Qu, X.; Chen, D.; Servos, M.;
368 Mak̈ila,̈ E.; Salonen, J.; Santos, H. A.; Hai, M.; Weitz, D. A. Adv. Funct.
369 Mater. 2015, 25 (22), 3330−3340.
(5)370 Park, J. H.; Gu, L.; von Maltzahn, G.; Ruoslahti, E.; Bhatia, S. N.;
371 Sailor, M. J. Nat. Mater. 2009, 8 (4), 331−336.
(6)372 Tasciotti, E.; Liu, X.; Bhavane, R.; Plant, K.; Leonard, A. D.;
373 Price, B. K.; Cheng, M. M.; Decuzzi, P.; Tour, J. M.; Robertson, F.;
374 Ferrari, M. Nat. Nanotechnol. 2008, 3 (3), 151−157.
(7)375 Bimbo, L. M.; Denisova, O. V.; Mak̈ila,̈ E.; Kaasalainen, M.; De
376 Brabander, J. K.; Hirvonen, J.; Salonen, J.; Kakkola, L.; Kainov, D.;
377 Santos, H. A. ACS Nano 2013, 7 (8), 6884−6893.
(8)378 Parodi, A.; Quattrocchi, N.; van de Ven, A. L.; Chiappini, C.;
379 Evangelopoulos, M.; Martinez, J. O.; Brown, B. S.; Khaled, S. Z.; Yazdi,
380 I. K.; Enzo, M. V.; Isenhart, L.; Ferrari, M.; Tasciotti, E. Nat.
381 Nanotechnol. 2013, 8 (1), 61−68.
(9)382 Wang, C. F.; Sarparanta, M. P.; Mak̈ila,̈ E. M.; Hyvonen, M. L.;
383 Laakkonen, P. M.; Salonen, J. J.; Hirvonen, J. T.; Airaksinen, A. J.;
384 Santos, H. A. Biomaterials 2015, 48, 108−118.
(10)385 Vigderman, L.; Khanal, B. P.; Zubarev, E. R. Adv. Mater. 2012,
386 24 (36), 4811−4841.
(11)387 Huang, X.; Neretina, S.; El-Sayed, M. A. Adv. Mater. 2009, 21
388 (48), 4880−4910.
(12)389 Kah, J. C. Y.; Chen, J.; Zubieta, A.; Hamad-Schifferli, K. ACS
390 Nano 2012, 6 (8), 6730−6740.
(13) 391Zhang, H.; Liu, D.; Shahbazi, M. A.; Mak̈ila,̈ E.; Herranz-Blanco,
392B.; Salonen, J.; Hirvonen, J.; Santos, H. A. Adv. Mater. 2014, 26 (26),
3934497−4503.
(14) 394Liu, D.; Zhang, H.; Fontana, F.; Hirvonen, J. T.; Santos, H. A.
395Adv. Drug Delivery Rev. 2017, 26, 1856−1883.
(15) 396Kong, F.; Zhang, H.; Qu, X.; Zhang, X.; Chen, D.; Ding, R.;
397Mak̈ila,̈ E.; Salonen, J.; Santos, H. A.; Hai, M. Adv. Mater. 2016, 28
398(46), 10195−10203.
(16) 399Tacar, O.; Sriamornsak, P.; Dass, C. R. J. Pharm. Pharmacol.
4002013, 65 (2), 157−170.
(17) 401Hai, M.; Kong, F. J. Chem. Eng. Data 2008, 53 (3), 765−769.
(18) 402Zhang, H.; Qu, X.; Chen, H.; Kong, H.; Ding, R.; Chen, D.;
403Zhang, X.; Pei, H.; Santos, H. A.; Hai, M.; Weitz, D. A. Adv. Healthcare
404Mater. 2017, 6 (20), 1700664.
(19) 405Kaelin, W. G., Jr. Nat. Rev. Cancer 2005, 5 (9), 689−698.
Nano Letters Letter
DOI: 10.1021/acs.nanolett.7b05210
Nano Lett. XXXX, XXX, XXX−XXX
F
